Artemis Medicare Services Q3 FY26 Results: Revenue Grows 17.2% to INR 272 Crores, Plans Major Expansion

3 min read     Updated on 09 Feb 2026, 11:57 PM
scanx
Reviewed by
Radhika SScanX News Team
Overview

Artemis Medicare Services reported strong Q3 FY26 results with revenue of INR 272 crores (up 17.2% YoY) and EBITDA of INR 52 crores. Nine-month revenues reached INR 802 crores with net profit of INR 73 crores. The company announced a INR 700 crore fundraise to support expansion from 700-800 beds to 2,000-2,300 beds by 2029, including new facilities in Raipur (300 beds, operational April-May 2026) and South Delhi (650 beds by 2029). International patient revenue grew 34.9%, contributing 34% of total revenues.

32207226

*this image is generated using AI for illustrative purposes only.

Artemis Medicare Services delivered robust financial performance in Q3 FY26, demonstrating strong growth across key operational metrics while announcing ambitious expansion plans that will significantly scale its healthcare infrastructure over the next few years.

Financial Performance Highlights

The company's financial results for Q3 FY26 showed consistent growth momentum across all major parameters:

Metric Q3 FY26 Growth (YoY)
Consolidated Revenue INR 272 crores +17.2%
EBITDA INR 52 crores Strong improvement
EBITDA Margin 9.1% Improved
Profit After Tax INR 22 crores +7.9%

For the nine-month period ending December 2025, the company reported consolidated revenues of INR 802 crores, representing a 15.1% year-on-year increase. EBITDA for nine months FY26 reached INR 159 crores with a margin of 19.8%, while net profit stood at INR 73 crores compared to INR 59 crores in the corresponding period of FY25.

Operational Excellence and Key Metrics

Artemis Medicare's flagship facility in Gurugram maintained strong operational performance with several key indicators showing positive trends:

Parameter Q3 FY26 Performance
Occupancy Rate 62%
Average Revenue Per Bed (ARPOB) INR 84,100
ARPOB Growth +10% YoY
International Patient Revenue Growth +34.9%
International Revenue Share 34% of total revenues

The company's international patient revenue demonstrated exceptional growth of 34.9%, contributing INR 89 crores to total revenues. This growth reflects Artemis Medicare's strong position in medical tourism, serving patients from 52 countries across the Middle East, Africa, and CIS regions.

Major Expansion Plans and Fundraising

Artemis Medicare announced a comprehensive expansion strategy that will transform its scale and reach. The company's board has approved a INR 700 crore fundraise through a combination of Qualified Institutional Placement (QIP) and preferential allotment to fund this ambitious growth plan.

Current and Planned Facilities

Facility Beds Timeline Status
Current Operations 700-800 Operational Active
Raipur Super Specialty 300 April-May 2026 Under commissioning
South Delhi (VIMHANS) 650 2029 Contract signing by FY26 end
Additional Projects TBA 2029 In pipeline
Total Target 2,000-2,300 By 2029 Planned

The Raipur facility represents a capex investment of INR 100 crores for 300 beds, structured as a long-term lease arrangement. The facility will begin operations with 200 beds, scaling to full capacity within 18 months, with expected ARPOB of INR 30,000 to INR 35,000 initially.

Strategic Infrastructure Developments

The company achieved significant milestones in infrastructure enhancement during the quarter. Artemis Medicare received platinum green building certification, which entitles the company to a 15% increase in Floor Area Ratio (FAR). This certification allows the addition of 100 to 125 more beds to the Gurugram facility at no additional land cost.

The South Delhi facility, planned as a 650-bed super specialty hospital, will be developed on trust land with an estimated cost of INR 75 to INR 80 lakhs per bed. This compares favorably to typical South Delhi healthcare facility costs of INR 1.75 to INR 2 crores per bed.

Technology and Service Expansion

Artemis Medicare continued investing in advanced medical capabilities and digital transformation initiatives. The company implemented AI-assisted triage systems across facilities to enhance patient experience and operational efficiency. New service lines launched during the quarter include:

  • Heart-lung transplant programs
  • Advanced robotic surgery capabilities
  • Comprehensive geriatrics packages
  • Enhanced oncology and organ transplant services

These high-value service additions, while requiring initial manpower investments, are expected to generate significant returns with procedures ranging from INR 35 to INR 55 lakhs for heart-lung transplants and INR 5 to INR 7 lakhs for annual geriatric packages.

Financial Strategy and Debt Management

The planned fundraising will enable the company to maintain conservative debt levels while funding aggressive expansion. Management indicated that maximum debt levels will remain below INR 300 crores, specifically in the INR 250 to INR 280 crore range, even with the substantial expansion program.

The fundraising structure ensures promoter majority retention, with current promoter shareholding at 58.3% post-CCD conversion, and commitment to maintain above 50% ownership even after the new fundraise.

Historical Stock Returns for Artemis Medicare Services

1 Day5 Days1 Month6 Months1 Year5 Years
+4.85%-8.10%-15.61%-7.85%-21.62%+957.36%
Artemis Medicare Services
View Company Insights
View All News
like15
dislike

Artemis Medicare Services Submits Q3FY26 Monitoring Agency Report for ₹330 Crore Preferential Issue

2 min read     Updated on 02 Feb 2026, 07:53 PM
scanx
Reviewed by
Ashish TScanX News Team
Overview

Artemis Medicare Services Limited submitted its Q3FY26 monitoring agency report showing ₹0.33 crore utilization from its ₹330 crore preferential issue proceeds for stamp duty payments. The company maintains ₹267.73 crore in unutilized funds invested across fixed deposits with major banks, earning ₹8.46 crore in interest. CARE Ratings Limited confirmed no deviations from stated objectives, with the completion timeline extending until May 15, 2026.

31587798

*this image is generated using AI for illustrative purposes only.

Artemis Medicare Services Limited has submitted its quarterly monitoring agency report for Q3FY26, detailing the utilization of proceeds from its ₹330 crore preferential issue. The report, prepared by CARE Ratings Limited as the monitoring agency, was reviewed and approved by the company's Audit Committee on February 2, 2026.

Minimal Utilization During Q3FY26

During the quarter ended December 31, 2025, the company utilized ₹0.33 crore from the issue proceeds for general corporate purposes. This amount was specifically used to pay stamp duty on the issuance of equity shares against the conversion of compulsorily convertible debentures held by International Finance Corporation (IFC).

Utilization Parameter Amount (₹ Crore)
Total Issue Size 330.00
Utilized During Q3FY26 0.33
Total Utilized to Date 62.27
Remaining Unutilized 267.73

Issue Objectives and Progress

The preferential issue was structured with two primary objectives. The major portion of ₹320 crore was allocated to support acquisition, expansion, and capital expenditure requirements of the company and its subsidiaries. An additional ₹10 crore was designated for general corporate purposes.

Objective Allocated Amount (₹ Crore) Utilized to Date (₹ Crore) Remaining (₹ Crore)
Acquisition & Capital Expenditure 320.00 54.00 266.00
General Corporate Purposes 10.00 8.27 1.73

Deployment of Unutilized Proceeds

The company has strategically deployed its unutilized proceeds across multiple fixed deposits with leading banks to generate returns while maintaining liquidity. The investments are spread across HDFC Bank, ICICI Bank, and Axis Bank with varying maturity dates and interest rates.

Fixed Deposit Portfolio

Bank Amount (₹ Crore) Maturity Date Interest Rate Earnings (₹ Crore)
HDFC Bank (0660) 28.36 May 19, 2026 6.95% 1.19
HDFC Bank (9917) 79.00 May 17, 2026 6.95% 3.32
ICICI Bank (2309) 80.00 November 10, 2026 6.15% 0.57
Axis Bank (0778) 80.00 May 16, 2026 6.90% 3.38
HDFC Bank (6853) 0.41 April 02, 2026 4.25% 0.00

The total interest earned on these investments amounts to ₹8.46 crore, with ₹0.05 crore from matured fixed deposits being reinvested.

Compliance and Monitoring

CARE Ratings Limited, serving as the monitoring agency under SEBI regulations, confirmed that all utilization aligns with the disclosures in the offer document. The agency reported no deviations from the stated objectives and confirmed that the proceeds have been appropriately utilized according to the subscription agreement.

The monitoring agency noted that the stamp duty payment was initially made from the company's current account on December 2, 2025, and subsequently reimbursed from the monitoring account in the same month. This transaction was supported by appropriate documentation including chartered accountant certificates, bank statements, and management certifications.

Regulatory Framework

The report was submitted pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 162A of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The completion timeline for the stated objectives extends until May 15, 2026, with the company maintaining its commitment to deploy the remaining funds as per the original plan.

Historical Stock Returns for Artemis Medicare Services

1 Day5 Days1 Month6 Months1 Year5 Years
+4.85%-8.10%-15.61%-7.85%-21.62%+957.36%
Artemis Medicare Services
View Company Insights
View All News
like20
dislike

More News on Artemis Medicare Services

1 Year Returns:-21.62%